Glucocorticoids increase cholecystokinin receptors and amylase secretion in pancreatic acinar AR42J cells.
We recently reported in AR42J pancreatic acinar cells that glucocorticoids increased the synthesis, cell content, and mRNA levels for amylase (Logsdon, C.D., Moessner, A., Williams, J.A., and Goldfine, I.D. (1985) J. Cell Biol. 100, 1200-1208). In addition, in these cells glucocorticoids increased the volume density of secretory granules and rough endoplasmic reticulum. In the present study we investigate the effects of glucocorticoids on the receptor binding and biological effects of cholecystokinin (CCK) on AR42J cells. Treatment with 10 nM dexamethasone for 48 h increased the specific binding of 125I-CCK. This increase in binding was time-dependent, with maximal effects occurring after 48 h, and dose-dependent, with a one-half maximal effect elicited by 1 nM dexamethasone. Other steroid analogs were also effective and their potencies paralleled their relative effectiveness as glucocorticoids. Analyses of competitive binding experiments conducted at 4 degrees C to minimize hormone internalization and degradation revealed the presence of a single class of CCK binding sites with a Kd of approximately 6 nM and indicated that dexamethasone treatment nearly tripled the number of CCK receptors/cell with little change in receptor affinity. Treatment with 10 nM dexamethasone increased both basal amylase secretion and the amylase released in response to CCK stimulation. In addition, dexamethasone increased the sensitivity of the cells to CCK. The glucocorticoid decreased the concentration of CCK required for one half-maximal stimulation of amylase secretion from 35 +/- 6 to 8 +/- 1 pM. These data indicate, therefore, that glucocorticoids induce an increase in the number of CCK receptors in AR42J cells, and this increase leads to enhanced sensitivity to CCK.
Logsdon
C D
CD
D000450:Aldosterone / Q000494:pharmacology; D000681:Amylases / Q000378:metabolism*; D000818:Animals; D002460:Cell Line; D002766:Cholecystokinin / Q000494:pharmacology*; D003345:Corticosterone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D011949:Receptors, Cholecystokinin; D012636:Secretory Rate / Q000187:drug effects
D005938:Glucocorticoids; D011956:Receptors, Cell Surface; D011949:Receptors, Cholecystokinin; D000450:Aldosterone; D011374:Progesterone; D004958:Estradiol; D003907:Dexamethasone; D002766:Cholecystokinin; D000681:Amylases; D003345:Corticosterone